Literature DB >> 25284834

Axillary Dissection in the Case of Positive Sentinel Lymph Nodes: Results of the Innsbruck Consensus Conference.

M Hubalek1, R Bartsch2, M Gnant3, K S Kapp4, A Lang5, S Lax6, P Lukas7, W Neunteufel8, G Pristauz9, R Reitsamer10, P Sandbichler11, P Schrenk12, C Singer13, K Tamussino9, J Tschmelitsch14, A G Zeimet1, C Marth1.   

Abstract

The prognosis of breast cancer is most heavily influenced by the status of the axillary nodes. Until a few years ago, this knowledge was gained through radical axillary lymph node clearance. In the meantime, sentinel lymph node clearance has become an established part of the surgical treatment of breast cancer. With the development of this procedure, the morbidity caused by axillary dissection has been reduced significantly. Although comprehensive prospective, randomised data regarding the safe use of the sentinel concept are only now available, the focus currently, however, is on the question of whether in the case of positive sentinel lymph nodes, an axillary dissection can be done away with altogether without having any negative impact on the risk of loco-regional recurrence or on progression-free survival and overall survival. The results of the American ACOSOG-Z001 study have changed the fundamental perspective of this. In this study on the advantages of axillary dissection following the confirmation of tumour tissue in the sentinel lymph nodes, there were no statistically significant advantages from axillary dissection for women with a favourable overall risk profile who had received radiotherapy and systemic therapy. If this concept takes hold, the surgical treatment of node-positive breast cancer, at least in the axilla, would be reduced to a minimum, and the focus of treatment would in future lie more on the systemic treatment of this condition. As part of an interdisciplinary consensus meeting, a standardised approach for Austria with regard to this question was decided upon.

Entities:  

Keywords:  ACOSOG-Z0011; axillary dissection; breast cancer; sentinel lymph node

Year:  2012        PMID: 25284834      PMCID: PMC4168401          DOI: 10.1055/s-0031-1298441

Source DB:  PubMed          Journal:  Geburtshilfe Frauenheilkd        ISSN: 0016-5751            Impact factor:   2.915


  9 in total

1.  Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation.

Authors:  Bernard Fisher; Jong-Hyeon Jeong; Stewart Anderson; John Bryant; Edwin R Fisher; Norman Wolmark
Journal:  N Engl J Med       Date:  2002-08-22       Impact factor: 91.245

Review 2.  Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials.

Authors:  M Clarke; R Collins; S Darby; C Davies; P Elphinstone; V Evans; J Godwin; R Gray; C Hicks; S James; E MacKinnon; P McGale; T McHugh; R Peto; C Taylor; Y Wang
Journal:  Lancet       Date:  2005-12-17       Impact factor: 79.321

3.  Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database.

Authors:  Min Yi; Sharon Hermes Giordano; Funda Meric-Bernstam; Elizabeth A Mittendorf; Henry M Kuerer; Rosa F Hwang; Isabelle Bedrosian; Loren Rourke; Kelly K Hunt
Journal:  Ann Surg Oncol       Date:  2010-09-19       Impact factor: 5.344

4.  Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study.

Authors:  Umberto Veronesi; Giuseppe Viale; Giovanni Paganelli; Stefano Zurrida; Alberto Luini; Viviana Galimberti; Paolo Veronesi; Mattia Intra; Patrick Maisonneuve; Francesca Zucca; Giovanna Gatti; Giovanni Mazzarol; Concetta De Cicco; Dario Vezzoli
Journal:  Ann Surg       Date:  2010-04       Impact factor: 12.969

5.  Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial.

Authors:  Robert E Mansel; Lesley Fallowfield; Mark Kissin; Amit Goyal; Robert G Newcombe; J Michael Dixon; Constantinos Yiangou; Kieran Horgan; Nigel Bundred; Ian Monypenny; David England; Mark Sibbering; Tholkifl I Abdullah; Lester Barr; Utheshtra Chetty; Dudley H Sinnett; Anne Fleissig; Dayalan Clarke; Peter J Ell
Journal:  J Natl Cancer Inst       Date:  2006-05-03       Impact factor: 13.506

6.  Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.

Authors:  Armando E Giuliano; Kelly K Hunt; Karla V Ballman; Peter D Beitsch; Pat W Whitworth; Peter W Blumencranz; A Marilyn Leitch; Sukamal Saha; Linda M McCall; Monica Morrow
Journal:  JAMA       Date:  2011-02-09       Impact factor: 56.272

7.  The value of cytokeratin immunohistochemistry in the evaluation of axillary sentinel lymph nodes in patients with lobular breast carcinoma.

Authors:  G Cserni; S Bianchi; V Vezzosi; H Peterse; A Sapino; R Arisio; A Reiner-Concin; P Regitnig; J-P Bellocq; C Marin; R Bori; J M Penuela; A Córdoba Iturriagagoitia
Journal:  J Clin Pathol       Date:  2006-02-23       Impact factor: 3.411

8.  Micrometastases or isolated tumor cells and the outcome of breast cancer.

Authors:  Maaike de Boer; Carolien H M van Deurzen; Jos A A M van Dijck; George F Borm; Paul J van Diest; Eddy M M Adang; Johan W R Nortier; Emiel J T Rutgers; Caroline Seynaeve; Marian B E Menke-Pluymers; Peter Bult; Vivianne C G Tjan-Heijnen
Journal:  N Engl J Med       Date:  2009-08-13       Impact factor: 91.245

9.  Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer.

Authors:  Karl Y Bilimoria; David J Bentrem; Nora M Hansen; Kevin P Bethke; Alfred W Rademaker; Clifford Y Ko; David P Winchester; David J Winchester
Journal:  J Clin Oncol       Date:  2009-04-13       Impact factor: 44.544

  9 in total
  2 in total

1.  Axillary Lymph Node Status in Early-Stage Breast Cancer Patients with Sentinel Node Micrometastases (0.2-2 mm).

Authors:  Johannes Bargehr; Michael Edlinger; Michael Hubalek; Christian Marth; Roland Reitsamer
Journal:  Breast Care (Basel)       Date:  2013-06       Impact factor: 2.860

2.  ICG Fluorescence Technique for the Detection of Sentinel Lymph Nodes in Breast Cancer: Results of a Prospective Open-label Clinical Trial.

Authors:  E-M Grischke; C Röhm; M Hahn; G Helms; S Brucker; D Wallwiener
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-09       Impact factor: 2.915

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.